N6-methyladenosine methylation analysis of long noncoding RNAs and mRNAs in 5-FU-resistant colon cancer cells

References

• Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer. Lancet. 2019;10207(394):1467–22. doi: 10.1016/S0140-6736(19)32319-0
   Google Scholar
• Vodenkova S, Buchler T, Cervena K, et al. 5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future. Pharmacol Ther. 2020;206:107447. doi: 10.1016/j.pharmthera.2019.107447
   PubMed Web of Science ®Google Scholar
• Liu R, Chen Y, Liu G, et al. PI3K/AKT pathway as a key link modulates the multidrug resistance of cancers. Cell Death Dis. 2020;9(11):797. doi: 10.1038/s41419-020-02998-6
   Google Scholar
• Shen Y, Tong M, Liang Q, et al. Epigenomics alternations and dynamic transcriptional changes in responses to 5-fluorouracil stimulation reveal mechanisms of acquired drug resistance of colorectal cancer cells. Pharmacogenomics J. 2018;1(18):23–28. doi: 10.1038/tpj.2016.91
   Google Scholar
• Hasan Abdali M, Afshar S, Sedighi Pashaki A, et al. Investigating the effect of radiosensitizer for ursolic acid and kamolonol acetate on HCT-116 cell line. Bioorg Med Chem. 2020;1(28):115152. doi: 10.1016/j.bmc.2019.115152
   Google Scholar
• Crea F, Nobili S, Paolicchi E, et al. Epigenetics and chemoresistance in colorectal cancer: an opportunity for treatment tailoring and novel therapeutic strategies. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. Drug Resist Updat. 2011;6(6):280–296. doi: 10.1016/j.drup.2011.08.001
   Google Scholar
• Blondy S, David V, Verdier M, et al. 5-fluorouracil resistance mechanisms in colorectal cancer: from classical pathways to promising processes. Cancer Sci. 2020;9(111):3142–3154. doi: 10.1111/cas.14532
   Google Scholar
• Afshar S, Sedighi Pashaki A, Najafi R, et al. Cross-resistance of acquired radioresistant colorectal cancer cell line to gefitinib and regorafenib. Iran J Med Sci. 2020;1(45):50–58.
   Google Scholar
• Azwar S, Seow HF, Abdullah M, et al. Recent updates on mechanisms of resistance to 5-fluorouracil and reversal strategies in colon cancer treatment. Biology. 2021;10(9):854. doi: 10.3390/biology10090854
   PubMedGoogle Scholar
• He L, Li H, Wu A, et al. Functions of N6-methyladenosine and its role in cancer. Mol Cancer. 2019;1(18):176. doi: 10.1186/s12943-019-1109-9
   Google Scholar
• Huang H, Weng H, Chen J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell. 2020;3(37):270–288. doi: 10.1016/j.ccell.2020.02.004
   Google Scholar
• Kasowitz SD, Ma J, Anderson SJ, et al. Nuclear m6A reader YTHDC1 regulates alternative polyadenylation and splicing during mouse oocyte development. PLoS Genet. 2018;5(14):e1007412. doi: 10.1371/journal.pgen.1007412
   Google Scholar
• Zhang L, Wan Y, Zhang Z, et al. IGF2BP1 overexpression stabilizes PEG10 mRNA in an m6A-dependent manner and promotes endometrial cancer progression. Theranostics. 2021;3(11):1100–1114. doi: 10.7150/thno.49345
   Google Scholar
• Chen C, Guo Y, Guo Y, et al. m6A modification in non-coding RNA: the role in cancer drug resistance. Front Oncol. 2021;11:746789. doi: 10.3389/fonc.2021.746789
   PubMedGoogle Scholar
• Xiong G, Liu C, Yang G, et al. Long noncoding RNA GSTM3TV2 upregulates LAT2 and OLR1 by competitively sponging let-7 to promote gemcitabine resistance in pancreatic cancer. J Hematol Oncol. 2019;1(12):97. doi: 10.1186/s13045-019-0777-7
   Google Scholar
• Chen Y-T, Xiang D, Zhao X-Y, et al. Upregulation of lncRNA NIFK-AS1 in hepatocellular carcinoma by m6A methylation promotes disease progression and sorafenib resistance. Hum Cell. 2021;6(34):1800–1811. doi: 10.1007/s13577-021-00587-z
   Google Scholar
• Chen S, Zhou Y, Chen Y, et al. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;17(34):i884–i890. doi: 10.1093/bioinformatics/bty560
   Google Scholar
• Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;4(12):357–360. doi: 10.1038/nmeth.3317
   Google Scholar
• Meng J, Lu Z, Liu H, et al. A protocol for RNA methylation differential analysis with MeRIP-Seq data and exomePeak R/Bioconductor package. Methods. 2014;3(69):274–281. doi: 10.1016/j.ymeth.2014.06.008
   Google Scholar
• Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell. 2010;4(38):576–589. doi: 10.1016/j.molcel.2010.05.004
   Google Scholar
• Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;1(26):139–140. doi: 10.1093/bioinformatics/btp616
   Google Scholar
• Derrien T, Guigó R, Johnson R. The long non-coding RNAs: a new (P)layer in the “dark matter”. Front Genet. 2011;2:107. doi: 10.3389/fgene.2011.00107
   PubMedGoogle Scholar
• Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;3(172):393–407. doi: 10.1016/j.cell.2018.01.011
   Google Scholar
• Xiao Y, Wang Y, Tang Q, et al. An elongation- and ligation-based qPCR Amplification method for the radiolabeling-free detection of locus-specific N6 -methyladenosine modification. Angew Chem Int Ed Engl. 2018;49(57):15995–16000. doi: 10.1002/anie.201807942
   Google Scholar
• Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;4(25):402–408. doi: 10.1006/meth.2001.1262
   Google Scholar
• Zhu W, Wang J-Z, Xu Z, et al. Detection of N6‑methyladenosine modification residues (review). Int J Mol Med. 2019;6(43):2267–2278. doi: 10.3892/ijmm.2019.4169
   Google Scholar
• Li J, Liang L, Yang Y, et al. N6-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction. Theranostics. 2021;6(11):2581–2593. doi: 10.7150/thno.52366
   Google Scholar
• Zhou X, Chen Z, Zhou J, et al. Transcriptome and N6-methyladenosine RNA methylome analyses in aortic dissection and normal human aorta. Front Cardiovasc Med. 2021;8:627380. doi: 10.3389/fcvm.2021.627380
   PubMed Web of Science ®Google Scholar
• Li A, Gan Y, Cao C, et al. Transcriptome-wide map of N6-methyladenosine methylome profiling in human bladder cancer. Front Oncol. 2021;11:717622. doi: 10.3389/fonc.2021.717622
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang Q, Zhang M, et al. Comprehensive analysis of the transcriptome-wide m6A methylome in colorectal cancer by MeRIP sequencing. Epigenetics. 2021;4(16):425–435. doi: 10.1080/15592294.2020.1805684
   Google Scholar
• Wang K, Peng J, Yi C. The m6A consensus motif provides a paradigm of epitranscriptomic studies. Biochemistry. 2021;46(60):3410–3412. doi: 10.1021/acs.biochem.1c00254
   Google Scholar
• Zhang C, Chen Y, Sun B, et al. m6A modulates haematopoietic stem and progenitor cell specification. Nature. 2017;7671(549):273–276. doi: 10.1038/nature23883
   Google Scholar
• Yang H, Wu Y-F, Ding J, et al. Comprehensive analysis of N6-methyladenosine (m6A) methylation in neuromyelitis optica spectrum disorders. Front Genet. 2021;12:735454. doi: 10.3389/fgene.2021.735454
   PubMed Web of Science ®Google Scholar
• Hong S, Shen X, Cheng J, et al. Comprehensive analysis of the transcriptome-wide m6A methylation in mouse pachytene spermatocytes and round spermatids. Front Genet. 2022;13:832677. doi: 10.3389/fgene.2022.832677
   PubMed Web of Science ®Google Scholar
• Yang G, Huang L, Jia H, et al. NDRG1 enhances the sensitivity of cetuximab by modulating EGFR trafficking in colorectal cancer. Oncogene. 2021;41(40):5993–6006. doi: 10.1038/s41388-021-01962-8
   Google Scholar
• Bashaw GJ, Klein R. Signaling from axon guidance receptors. Cold Spring Harb Perspect Biol. 2010;5(2):a001941. doi: 10.1101/cshperspect.a001941
   Google Scholar
• Rashidi G, Rezaeepoor M, Mohammadi C, et al. Inhibition of semaphorin 4D enhances chemosensitivity by increasing 5-fluorouracile-induced apoptosis in colorectal cancer cells. Mol Biol Rep. 2020;9(47):7017–7027. doi: 10.1007/s11033-020-05761-4
   Google Scholar
• Li L, Xu N, Zhang J-F, et al. EphB4/ephrinB2 contributes to imatinib resistance in chronic myeloid leukemia involved in cytoskeletal proteins. Int J Med Sci. 2016;5(13):365–373. doi: 10.7150/ijms.14989
   Google Scholar
• Liu J, Bi J, Li Z, et al. miR‑214 reduces cisplatin resistance by targeting netrin‑1 in bladder cancer cells. Int J Mol Med. 2018;3(41):1765–1773. doi: 10.3892/ijmm.2018.3374
   Google Scholar
• Wey JS, Gray MJ, Fan F, et al. Overexpression of neuropilin-1 promotes constitutive MAPK signalling and chemoresistance in pancreatic cancer cells. Br J Cancer. 2005;2(93):233–241. doi: 10.1038/sj.bjc.6602663
   Google Scholar
• Kong J, Fang P, Madoux F, et al. High-throughput screening for protein synthesis inhibitors targeting aminoacyl-tRNA synthetases. SLAS Discov. 2018;2(23):174–182. doi: 10.1177/2472555217734128
   Google Scholar
• Francklyn CS, Mullen P. Progress and challenges in aminoacyl-tRNA synthetase-based therapeutics. J Biol Chem. 2019;14(294):5365–5385. doi: 10.1074/jbc.REV118.002956
   Google Scholar
• Shi Y, Wang Y, Huang W, et al. Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in nonsmall cell lung cancer. J Proteome Res. 2019;9(18):3259–3267. doi: 10.1021/acs.jproteome.9b00209
   Google Scholar
• Usman RM, Razzaq F, Akbar A, et al. Role and mechanism of autophagy-regulating factors in tumorigenesis and drug resistance. Asia Pac J Clin Oncol. 2021;3(17):193–208. doi: 10.1111/ajco.13449
   Google Scholar
• Zhao L, Chen H, Zhang Q, et al. ATF4-mediated microRNA-145/HDAC4/p53 axis affects resistance of colorectal cancer cells to 5-fluorouracil by regulating autophagy. Cancer Chemother Pharmacol. 2022;5(89):595–607. doi: 10.1007/s00280-021-04393-0
   Google Scholar
• Xuan Y, Zhao S, Xiao X, et al. Inhibition of chaperone‑mediated autophagy reduces tumor growth and metastasis and promotes drug sensitivity in colorectal cancer. Mol Med Rep. 2021;5(23). doi: 10.3892/mmr.2021.11999
   Google Scholar
• Fakhr E, Zare F, Azadmanesh K, et al. LEF1 silencing sensitizes colorectal cancer cells to oxaliplatin, 5-FU, and irinotecan. Biomed Pharmacother. 2021;143:112091. doi: 10.1016/j.biopha.2021.112091
   PubMed Web of Science ®Google Scholar
• Park S-Y, Kim J-Y, Choi J-H, et al. Inhibition of LEF1-mediated DCLK1 by niclosamide attenuates colorectal cancer stemness. Clin Cancer Res. 2019;4(25):1415–1429. doi: 10.1158/1078-0432.CCR-18-1232
   Google Scholar
• Zhang G, Luo X, Wang Z, et al. TIMP-2 regulates 5-fu resistance via the ERK/MAPK signaling pathway in colorectal cancer. Aging. 2022;1(14):297–315. doi: 10.18632/aging.203793
   Google Scholar
• Liu Z, Lu J, Fang H, et al. m6A modification-mediated DUXAP8 regulation of malignant phenotype and chemotherapy resistance of hepatocellular carcinoma through miR-584-5p/MAPK1/ERK pathway axis. Front Cell Dev Biol. 2021;9:783385. doi: 10.3389/fcell.2021.783385
   PubMed Web of Science ®Google Scholar
• Bhosale PB, Kim HH, Abusaliya A, et al. Structural and functional properties of activator protein-1 in cancer and inflammation. Evid Based Complement Alternat Med. 2022;2022:9797929. doi: 10.1155/2022/9797929
   PubMed Web of Science ®Google Scholar
• Zhao Y, Luo A, Li S, et al. Inhibitor of differentiation/DNA binding 1 (ID1) inhibits etoposide-induced apoptosis in a c-Jun/c-fos-dependent manner. J Biol Chem. 2016;13(291):6831–6842. doi: 10.1074/jbc.M115.704361
   Google Scholar
• Zhu Q, Chen J, Pan P, et al. UBE2N Regulates Paclitaxel Sensitivity of Ovarian Cancer via Fos/P53 Axis. Onco Targets Ther. 2020;13:12751–12761. doi: 10.2147/OTT.S271164
   PubMed Web of Science ®Google Scholar
• Kang Y-S, Seok H-J, Jeong E-J, et al. DUSP1 induces paclitaxel resistance through the regulation of p-glycoprotein expression in human ovarian cancer cells. Biochem Biophys Res Commun. 2016;1(478):403–409. doi: 10.1016/j.bbrc.2016.07.035
   Google Scholar
• Teng F, Xu Z, Chen J, et al. DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer. Oncol Rep. 2018;3(40):1203–1222. doi: 10.3892/or.2018.6520
   Google Scholar
• Zandi Z, Kashani B, Alishahi Z, et al. Dual-specificity phosphatases: therapeutic targets in cancer therapy resistance. J Cancer Res Clin Oncol. 2022;1(148):57–70. doi: 10.1007/s00432-021-03874-2
   Google Scholar
• Kesarwani M, Kincaid Z, Gomaa A, et al. Targeting c-FOS and DUSP1 abrogates intrinsic resistance to tyrosine-kinase inhibitor therapy in BCR-ABL-induced leukemia. Nat Med. 2017;4(23):472–482. doi: 10.1038/nm.4310
   Google Scholar
• Kang H, Kim C, Ji E, et al. The MicroRNA-551a/MEF2C axis regulates the survival and sphere formation of cancer cells in response to 5-fluorouracil. Mol Cells. 2019;2(42):175–182.
   Google Scholar